Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia

25

CAMBRIDGE, Mass. & BASEL, Switzerland–(BUSINESS WIRE)–Enzyvant announces FDA acceptance of its BLA for RVT-802, a novel investigational tissue-based regenerative therapy for pediatric congenital athymia.

 

 

 

 

http://www.businesswire.com/news/home/20190605005305/en/Enzyvant-Announces-FDA-Acceptance-Biologics-License-Application/